Full-Time

CSV Engineer

Confirmed live in the last 24 hours

Deadline 9/5/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

Compensation Overview

$74.3k - $123.8k/yr

Mid, Senior

East Side, PA, USA

In Person

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Bachelor’s or Master’s degree in Science, Engineering, or related Life Sciences or Technology fields.
  • A minimum 4-7 years of relevant experience, preferably in Validation and/or Quality in the pharmaceutical or biotechnology industry.
  • Sound knowledge and understanding of regulatory (including FDA 21 CFR Part 11, EU Annex 11) and GAMP requirements, and industry best practices (e.g., ISO, ISPE, PDA) pertaining to CSV.
  • Working knowledge of quality risk management methods and tools, including Failure Mode Effects Analysis (FMEA), Fault Tree Analysis (FTA), and their application to the validation of computerized systems.
  • Solid technical knowledge in the use and application of risk- and science-based approaches to CSV.
  • Driven team player with the ability to collaborate and work with cross-functional teams (including global partners) to meet project timelines.
  • Good communication skills to present validation strategies to the site management and other functions.
  • Familiar with Digital 4.0 concepts and control systems.
  • Able to work independently with little supervision.
  • Experience with ensuring Data Integrity in computerized systems.
  • Expertise in OT system validation processes and lifecycle.
  • Knowledge of security patch management for control systems.
  • Experience in backup protocol development and validation.
  • Ability to analyze deviations and implement corrective actions.
  • Understanding of regulatory and industry standards for OT systems.
  • Strong problem-solving and documentation skills.
  • Knowledge in DCS, PLC, SCADA, BMS, EMS and HMI systems.
  • Understanding of ISA-95, ISA-88 standards.
  • Problem-solving and project management skills.
Responsibilities
  • Ensure all Computerized Systems Validation (CSV) lifecycle activities meet Sanofi’s quality requirements and fulfill regulatory expectations.
  • Design and execute validation protocols and testing.
  • Create and manage validation documentation.
  • Troubleshoot validation issues, conduct risk assessments and support audit.
  • Record and analyze deviations and downtime for root cause identification.
  • Provide technical expertise in CS validation lifecycle for OT systems.
  • Ensure OT systems comply with regulatory and industry standards.
  • Collaborate with cross-functional teams, including IT, Automation, and Manufacturing, in defining and implementing risk-based validation strategy to demonstrate the computerized systems are fit for intended use throughout entire life cycle, and to ensure that computerized systems are qualified and maintained accordingly.
  • Lead and provide quality oversight for establishing and maintaining site’s computerized systems validation program in accordance with current regulatory expectations, Sanofi standards, and industry practices.
  • Function as a key quality reviewer and approver of CSV lifecycle documents, including user requirements/functional specifications, validation plans, risk assessments (e.g., system criticality assessment, functional risks assessment, data integrity risk assessments), protocols, and reports.
  • Author CSV plans and procedures.
  • Coordinate and provide oversight for the documentation and maintenance of computerized systems inventory.
  • Ensure continual improvement of CSV program by performing periodic review of the program.
  • Review, evaluate, and approve CSV related non-conformities and changes, and support investigations and corrective actions.
  • Ensure all qualification/validation activities are successfully concluded, all documentation completed, and all non-conformities addressed, before the computerized systems are released for GMP use.
  • Provide support during regulatory inspections and site audits as quality oversight and SME of CSV.
  • Partner and collaborate closely with cross functional teams to achieve site’s GMP/operational readiness goals/objectives and ensuring all project deliverables are met on time.
Desired Qualifications
  • Familiar with Digital 4.0 concepts and control systems.
  • Knowledge in DCS, PLC, SCADA, BMS, EMS and HMI systems.

Sanofi provides healthcare solutions through the development of treatments and vaccines. The company focuses on research and development to create new therapies for conditions in immunology, oncology, and rare diseases, as well as producing vaccines. Sanofi's products are designed to meet the needs of patients, healthcare professionals, and governments, offering a wide range of prescription medicines and over-the-counter products. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and extensive R&D efforts, which are supported by strategic partnerships and a diverse product pipeline. The company's goal is to improve health outcomes and enhance the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's acquisition of Blueprint Medicines expands its portfolio in rare immunological diseases.
  • The approval of Dupixent for chronic spontaneous urticaria opens new market opportunities.
  • Sanofi's investment in Adagene supports innovative cancer treatment development.

What critics are saying

  • Large-scale acquisitions may strain Sanofi's financial stability if returns are insufficient.
  • Regulatory challenges could delay the market entry of new treatments like tolebrutinib.
  • Dependence on strategic partnerships may pose risks if collaborations don't meet expectations.

What makes Sanofi unique

  • Sanofi's extensive R&D efforts focus on unmet medical needs in immunology and oncology.
  • The company leverages strategic partnerships to enhance its product pipeline and market reach.
  • Sanofi's global presence allows it to navigate diverse regulatory environments effectively.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Investors Hangout
Jul 1st, 2025
Adagene Secures $25M Investment from Sanofi

Adagene Inc. has secured a strategic investment of up to $25 million from Sanofi to advance its research and development, particularly for the clinical trials of muzastotug (ADG126), an anti-CTLA-4 SAFEbody targeting microsatellite stable colorectal cancer. This funding will extend Adagene's operational runway into 2027 and includes a phase 2 trial with over 100 patients. The partnership also allows Sanofi a role in Adagene's Scientific Advisory Board.

Sanofi
Jun 18th, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750...

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...